Piroxicam inhibits the growth of an adenocarcinoma isograft in Fischer rats.
The effect of piroxicam, a nonsteroidal anti-inflammatory drug, on a transplantable adenocarcinoma in Fischer rats was studied. Forty male Fischer rats were injected with 1 X 10(6) DMH-F317 adenocarcinoma cells, and after 2 weeks were assigned to be treated with piroxicam or carrier solution. The groups were as follows: Group 1, control; Group 2, 4.0 mg/kg piroxicam; Group 3, 6.0 mg/kg piroxicam; and Group 4, 8.0 mg/kg piroxicam. Thirty-nine of forty rats developed measurable tumors during this study. At the conclusion, 60% (6/10) of the rats in Group 2 were tumor free compared to 0/10 controls, 0/10 Group 3 rats, and 1/8 Group 4 rats. (P less than 0.005, chi 2). Mean tumor volumes (mm3) were calculated for each group and converted to log10. At Week 6, the mean log10 tumor volume (+/- SEM) for Group 2 was 1.5 +/- 0.6 vs 4.1 +/- 0.1 for Group 1 (P less than 0.05). The mean log10 volume for Group 3 was 3.8 +/- 0.1 (P less than 0.05 vs Group 2). The mean log10 volume for Group 4 was 3.4 +/- 0.05 and was not significantly different from that for Group 2 (P greater than 0.05). Plasma PGE2 levels for each treatment group were determined at the conclusion of the study and no statistical difference between treatment groups was found. It is concluded that piroxicam inhibits tumor growth in this model, and may have a role as a biological response modifier in cancer therapy.
Ross
D S
DS
Division of General Surgery, Southern Illinois University School of Medicine, Springfield 62794.
Bitzer
D
D
Roy
T
T
Murphy
J E
JE
D000230:Adenocarcinoma / Q000097:blood / Q000473:pathology*; D000818:Animals; D015232:Dinoprostone; D004305:Dose-Response Relationship, Drug; D008297:Male; D009368:Neoplasm Transplantation; D010894:Piroxicam / Q000494:pharmacology*; D011458:Prostaglandins E / Q000097:blood; D051381:Rats; D011916:Rats, Inbred F344
D011458:Prostaglandins E; D010894:Piroxicam; D015232:Dinoprostone